TARS - Tarsus Pharmaceuticals

-

$undefined

N/A

(N/A)

Tarsus Pharmaceuticals NasdaqGS:TARS Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Location: 15440 Laguna Canyon Road, Irvine, CA, 92618, United States | Website: https://www.tarsusrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.49B

Cash

407.9M

Avg Qtr Burn

-16.47M

Short % of Float

23.81%

Insider Ownership

3.23%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XDEMVY (TP-03) Details
Eye disease , Demodex Blepharitis

Approved

Quarterly sales

TP-03 Details
Meibomian Gland Disease , Demodex Blepharitis

Phase 3

Update

TP-04 Details
Ocular Rosacea

Phase 2

Initiation

TP-05 Details
Lyme disease

Phase 2a

Update

TP-04 Details
Papulopustular rosacea

Phase 2a

Update

TP-03 Details
Meibomian Gland Disease

Phase 2a

Update